|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0010583,
umls-concept:C0014582,
umls-concept:C0032659,
umls-concept:C0242957,
umls-concept:C0332293,
umls-concept:C0681890,
umls-concept:C0746319,
umls-concept:C0950521,
umls-concept:C1516213,
umls-concept:C1522673,
umls-concept:C2745888
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2001-10-3
|
|
pubmed:abstractText |
The predictive role of HER-2 in node-positive breast cancer patients receiving CMF or an anthracycline-based adjuvant therapy remains unclear. In addition, topo-isomerase II alpha (topo IIalpha), as the cellular target of anthracyclines, might have value as a predictive marker.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Topoisomerases, Type II,
http://linkedlifedata.com/resource/pubmed/chemical/DNA topoisomerase II alpha,
http://linkedlifedata.com/resource/pubmed/chemical/DNA-Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Epirubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:BeauduinMM,
pubmed-author:Closon-DejardinM TMT,
pubmed-author:Di LeoAA,
pubmed-author:DolciSS,
pubmed-author:FocanC HCH,
pubmed-author:GancbergDD,
pubmed-author:GobertP HPH,
pubmed-author:IsolaJJ,
pubmed-author:JarvinenTT,
pubmed-author:LarsimontDD,
pubmed-author:LobelleJ PJP,
pubmed-author:MichelJJ,
pubmed-author:PaesmansMM,
pubmed-author:PiccartM JMJ,
pubmed-author:RieuDD,
pubmed-author:RouasGG,
pubmed-author:VindevoghelAA
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1081-9
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:11583189-Adult,
pubmed-meshheading:11583189-Aged,
pubmed-meshheading:11583189-Antigens, Neoplasm,
pubmed-meshheading:11583189-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11583189-Breast Neoplasms,
pubmed-meshheading:11583189-Chemotherapy, Adjuvant,
pubmed-meshheading:11583189-Confidence Intervals,
pubmed-meshheading:11583189-Cyclophosphamide,
pubmed-meshheading:11583189-DNA Topoisomerases, Type II,
pubmed-meshheading:11583189-DNA-Binding Proteins,
pubmed-meshheading:11583189-Epirubicin,
pubmed-meshheading:11583189-Female,
pubmed-meshheading:11583189-Fluorouracil,
pubmed-meshheading:11583189-Genes, erbB-2,
pubmed-meshheading:11583189-Humans,
pubmed-meshheading:11583189-Methotrexate,
pubmed-meshheading:11583189-Middle Aged,
pubmed-meshheading:11583189-Predictive Value of Tests,
pubmed-meshheading:11583189-Prognosis,
pubmed-meshheading:11583189-Receptor, erbB-2,
pubmed-meshheading:11583189-Retrospective Studies,
pubmed-meshheading:11583189-Treatment Outcome,
pubmed-meshheading:11583189-Tumor Markers, Biological
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
|
|
pubmed:affiliation |
Department of Chemotherapy, Jules Bordet Institute, Brussels, Belgium. Angelo.Dileo@bordet.be
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III
|
